We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 31 for:    sinovac | China

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03274102
Recruitment Status : Recruiting
First Posted : September 6, 2017
Last Update Posted : September 8, 2017
Sponsor:
Collaborators:
Guangdong Provincial Center for Disease Control and Prevention
Dongguan Municipal Center for Disease Control and Prevention
Information provided by (Responsible Party):
Sinovac Biotech Co., Ltd

September 4, 2017
September 6, 2017
September 8, 2017
April 22, 2017
December 2017   (Final data collection date for primary outcome measure)
The seropositive rate of EV71 neutralizing antibody, anti-HBs and serum bactericidal antibody 1 month after 2 doses of vaccination [ Time Frame: 30 days after 2 doses of injection ]
Immunogenicity indicator
Same as current
Complete list of historical versions of study NCT03274102 on ClinicalTrials.gov Archive Site
  • Incidence of solicited local or systemic adverse events within 7 days after each dose [ Time Frame: 7 days after each dose of injection ]
    Safety indicator
  • Incidence of unsolicited local or systemic adverse events within 30 days after each dose [ Time Frame: 30 days after each dose of injection ]
    Safety indicator
  • Incidence of serious adverse events during the period of safety monitoring [ Time Frame: 60 days after the first dose injection ]
    Safety indicator
  • The seroconversion rate of EV71 neutralizing antibody, anti-HBs and serum bactericidal antibody(SBA) 1 month after 2 doses of vaccination [ Time Frame: 30 days after 2 doses of injection ]
    Immunogenicity indicator
  • EV71 neutralizing antibody GMT, anti-HBs GMC and SBA antibody GMT 1 month after 2 doses of vaccination [ Time Frame: 30 days after 2 doses of injection ]
    Immunogenicity indicator
Same as current
Not Provided
Not Provided
 
Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines
A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Recombinant Hepatitis B Vaccine/Group A Meningococcal Polysaccharide Vaccine
The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine with recombinant hepatitis B vaccine/Group A meningococcal polysaccharide vaccine.
This study is an open-label, single-center, randomized, comparative phase IV clinical trial. The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine manufactured by Sinovac (Beijing) Vaccine Technology Co., Ltd. with recombinant hepatitis B vaccine/Group A meningococcal polysaccharide vaccine. 780 healthy infants of 6 months old as participants are randomly assigned into three experimental groups in the ratio 1:1:1. The group I receive EV71 Vaccine (first dose)& recombinant hepatitis B vaccine on day 0 and EV71 vaccine (second dose)& Group A meningococcal polysaccharide vaccine on day 30. The group II receive recombinant hepatitis B vaccine on day 0 and Group A meningococcal polysaccharide vaccine on day 30. The group III receive the first and second dose of EV71 Vaccine on day 0 and day 30 respectively.
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Masking Description:
open-labelled
Primary Purpose: Prevention
Hand, Foot and Mouth Disease
  • Biological: Concomitant administration of EV71 vaccine with EPI vaccines
    1. The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.; the recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.
    2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study
  • Biological: Single injection of EPI vaccine
    1. The recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.
    2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study
  • Biological: EV71 Vaccine only
    The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
  • Experimental: Group I-EV71 vaccine and EPI vaccines
    Concomitant administration of EV71 vaccine with EPI vaccines: EV71 Vaccine (intramuscular injection,0.5ml,first dose)/recombinant hepatitis B vaccine(intramuscular injection,0.5ml)on day 0 and EV71 Vaccine (injection, 0.5ml,second dose)/ Group A meningococcal polysaccharide vaccine(subcutaneous injection, 150ug) on day 30.
    Intervention: Biological: Concomitant administration of EV71 vaccine with EPI vaccines
  • Active Comparator: Group II-EPI vaccine only
    Single injection of EPI vaccine: recombinant hepatitis B vaccine (intramuscular injection, 0.5ml) on day 0 and Group A meningococcal polysaccharide vaccine (subcutaneous injection,150ug) on day 30.
    Intervention: Biological: Single injection of EPI vaccine
  • Active Comparator: Group III-EV71 vaccine only
    EV71 Vaccine only: the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 and day 30 respectively.
    Intervention: Biological: EV71 Vaccine only
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
780
February 2018
December 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy volunteers aged 6 months
  • Finished two doses of vaccination (0,1 month) of hepatitis B vaccine prior to study entry
  • Proven legal identity
  • Guardian(s) of the volunteer should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study

Exclusion Criteria:

  • Finished all the three doses vaccination (0,1,6 month) of hepatitis B vaccine prior to study entry
  • Prior vaccination of meningococcal polysaccharide vaccine
  • Prior vaccination of EV71 vaccine
  • Unable to receive vaccination on both arms
  • History of hand foot and mouth disease
  • Previously tested HBsAg positive
  • Mother of the subject had been previously tested HBsAg positive
  • History of asthma; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc
  • Congenital malformation, developmental disorders, genetic defects
  • Autoimmune disease or immunodeficiency/immunosuppressive
  • Severe nervous system disease or mental illness
  • Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders
  • Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) within 6 month prior to study entry
  • Receipt of blood product (e.g., immunoglobulin) within 3 months prior to study entry
  • Receipt of any other investigational medicine(s) within 30 days prior to study entry
  • Receipt of any live attenuated vaccine within 14 days prior to study entry
  • Receipt of any subunit vaccine or inactivated vaccine within 7 days prior to study entry
  • Acute disease or acute stage of chronic disease within 7 days prior to study entry
  • Axillary temperature > 37.0 ℃
  • Any other factor that suggesting the volunteer is unsuitable for this study based on the judgement of investigators

Exclusion Criteria of the Second Injection:

  • Subjects with one of the following 1 to 3 conditions are forbidden to continue vaccination, while the other study steps could be carried out based on the judgement of investigator; for subjects with one of the following 4 to 5 conditions, whether to continue vaccination are determined by the investigator; for subjects with one of the following 6 to 7 conditions, vaccination may be delayed in the time window specified in the study:

    1. Any serious adverse event that has a causal relationship with the investigated vaccine (except the group II)
    2. Severe allergic reactions or hypersensitivity after vaccination (including urticaria / rash appear within 30 minutes after vaccination, except the group II )
    3. Any confirmed or suspected autoimmune disease or immunodeficiency disease (e.g., HIV infection)
    4. New chronic diseases or acute stage of chronic diseases
    5. Other reactions (including severe pain, severe swelling, severe activity limitation, persistent hyperthermia, severe headache or other systemic or local reactions) determined by the investigators
    6. Acute diseases (moderate or severe diseases with or without fever)
    7. Axillary temperature> 37.0 ℃
Sexes Eligible for Study: All
6 Months to 6 Months   (Child)
Yes
Contact: Huizhen Zheng 86-18922341069 zhzgd@vip.sina.com
China
 
 
NCT03274102
PRO-EV71-4003
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Sinovac Biotech Co., Ltd
Sinovac Biotech Co., Ltd
  • Guangdong Provincial Center for Disease Control and Prevention
  • Dongguan Municipal Center for Disease Control and Prevention
Principal Investigator: Huizhen Zheng Guangdong Provincial Center for Disease Control and Prevention
Sinovac Biotech Co., Ltd
September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP